Search
Patexia Research

Patent 07266410 - Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges > Claims

  • 1. A method for determining an increased likelihood of the occurrence of a myocardial ischemia or congestive heart failure, the method comprising:nmonitoring the left stellate ganglia nerve activity of the patient; anddetecting an increase in the left stellate ganglia nerve activity; andproducing a radio-transmitted signal in response to a detected increase in the left stellate ganglia nerve activity.
    • 2. The method of claim 1 wherein the step of monitoring the stellate ganglia nerve activity comprises implanting nanoelectrode array on the left stellate ganglion in the patient, wherein the nanoelectrode array senses the electrical activity of the left stellate ganglion.
      • 3. The method of claim 2 wherein the increase in the left stellate ganglia nerve activity is determined by an increase in the amplitude and/or frequency of the sensed electrical activity beyond a two fold increase of defined normal values.
      • 4. The method of claim 2 wherein the increase in the left stellate ganglia nerve activity is determined by comparing the monitored electrical activity and the normal electrical activity of the patient.
        • 5. The method of claim 4 wherein the output signal is an audible sound.
          • 6. The method of claim 5 further comprising the step of delivering therapy in response to a radio-transmitted signal, the therapy selected from any one or more of the group consisting of: delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks.
            • 7. The method of claim 6 wherein the one or more pharmacological agents is an anti-convulsant agent.
              • 8. The method of claim 7 wherein the anti-convulsant agent is selected from the group consisting of: phenytoin, carbamazepine, valproate, and phenobarbitone.
            • 9. The method of claim 6 wherein the one or more pharmacologic agent is suitable for the treatment of myocardial ischemia and is selected from the group consisting of: statins, angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta blockers, calcium channel blockers, and nitrates.
  • 10. A system for determining an increased likelihood of the occurrence of a myocardial ischemia or congestive heart failure, the system comprising:na nanoelectrode array sensor for acquiring data relating to the sympathetic neural discharges of a patient from the stellate ganglia or the thoracic ganglia;a processor programmed to receive the data acquired from the nanoelectrode array sensor, wherein the processor analyzes the data and determines if there is an increase in the sympathetic neural discharge; andan output unit for generating a radio transmitted output signal in response to a determined increase in the sympathetic neural discharge.
    • 11. The system of claim 10 wherein the nanoelectrode array sensor is an electrode that is implanted on the left stellate ganglion of the patient and wherein the electrode senses the electrical activity of the left stellate ganglion.
      • 12. The system of claim 11 wherein the processor determines that an increase in the sympathetic neural discharge has occurred by an increase in the amplitude or frequency of the sensed electrical activity beyond a two fold increase defined normal values.
      • 13. The system of claim 11 wherein the processor determines that an increase in the sympathetic neural discharge has occurred by comparing the sensed electrical activity and the normal electrical activity of the left stellate ganglion.
    • 14. The system of claim 10 wherein the output signal is an audible sound.
    • 15. The system of claim 10 wherein the output signal is a radio-transmitted signal.
      • 16. The system of claim 15 further comprising delivery module for delivering therapy in response to the radio-transmitted signal, the therapy selected from any one or more of the group consisting of: delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, and cardioversion or defibrillation shocks.
        • 17. The system of claim 16 wherein the one or more pharmacological agents is an anti-convulsant agent.
          • 18. The system of claim 17 wherein the anti-convulsant agent is selected from the group consisting of: phenytoin, carbamazepine, valproate, and phenobarbitone.
        • 19. The system of claim 16 wherein the one or more pharmacologic agent is suitable for the treatment of myocardial ischemia and is selected from the group consisting of: statins, angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta blockers, calcium channel blockers, and nitrates.
  • 20. A system for determining an increased likelihood of the occurrence of a myocardial ischemia or congestive heart failure associated with elevated sympathetic neural discharges in a patient, the system comprising:nmeans for monitoring the sympathetic neural discharges of a patient from the left stellate ganglia or the thoracic ganglia;means for determining an increase in the sympathetic neural discharge; andmeans for producing an output signal in response to a determined increase in the sympathetic neural discharge.
    • 21. The system of claim 20 wherein the means for monitoring sympathetic neural discharges comprises sensing the electrical activity of the left stellate ganglion using a nanoelectrode array.
      • 22. The system of claim 21 wherein the means for determining an increase in the sympathetic neural discharges comprises comparing the sensed electrical activity of the left stellate ganglion and the normal electrical activity of the left stellate ganglion.
      • 23. The system of claim 21 wherein the increase in the sympathetic neural discharge is determined by detecting an increase in the amplitude or frequency of the sensed electrical activity beyond a two fold increase of defined normal values.
    • 24. The system of claim 20 wherein the output signal is an audible sound.
    • 25. The system of claim 20 wherein the output signal is a radio-transmitted signal.
      • 26. The system of claim 25 further comprising means for delivering therapy in response to the radio-transmitted signal, the therapy selected from any one or more of the group consisting of: delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks.
        • 27. The system of claim 26 wherein the one or more pharmacological agents is an anti-convulsant agent.
          • 28. The system of claim 27 wherein the anti-convulsant agent is selected from the group consisting of: phenytoin, carbamazepine, valproate, and phenobarbitone.
        • 29. The system of claim 26 wherein the one or more pharmacologic agent is suitable for the treatment of myocardial ischemia and is selected from the group consisting of: statins, angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta blockers, calcium channel blockers, and nitrates.
  • 30. A method for determining an increased likelihood of the occurrence of a myocardial isehemia or congestive heart failure, the method comprising:nmonitoring the left stellate ganglia nerve activity of the patient by means of an implanted electrode on the left stellate ganglia of a patient;detecting an increase in the left stellate ganglia nerve activity; andproducing a radio-transmitted signal in response to a detected increase in the left stellate ganglia nerve activity.
    • 31. The method of claim 30 further comprising the step of delivering therapy in response to the radio-transmitted signal, the therapy selected from any one or more of the group consisting of: delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks.
      • 32. The method of claim 31 wherein the one or more pharmacological agents is an anti-convulsant agent.
        • 33. The method of claim 32 wherein the anti-convulsant agent is selected from the group consisting of: phenytoin, carbamazepine, valproate, and phenobarbitone.
      • 34. The method of claim 31 wherein the one or more pharmacologic agent is suitable for the treatment of myocardial ischemia and is selected from the group consisting of: statins, angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta blockers, calcium channel blockers, and nitrates.
  • 35. A system for determining an increased likelihood of the occurrence of a myocardial ischemia or congestive heart failure and other diseased condition of the heart associated with elevated sympathetic neural discharges in a patient, the system comprising:na sensor configured to acquire data relating to the sympathetic neural discharges of a patient from the left stellate ganglia;a processor programmed to receive the data acquired from the sensor, wherein the processor analyzes the data and determines if there is an increase in the sympathetic neural discharge; andan output unit for generating a radio transmitted output signal in response to a determined increase in the sympathetic neural discharge.
    • 36. The system of claim 35 further comprising a delivery module for delivering therapy in response to the command signal, the therapy selected from any one or more of the group consisting of: delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, and cardioversion or defibrillation shocks.
      • 37. The system of claim 36 wherein the one or more pharmacological agents is an anti-convulsant agent.
        • 38. The system of claim 37 wherein the anti-convulsant agent is selected from the group consisting of: phenytoin, carbamazepine, valproate, and phenobarbitone.
      • 39. The system of claim 36 wherein the one or more pharmacologic agent is suitable for the treatment of myocardial ischemia and is selected from the group consisting of: statins, angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta blockers, calcium channel blockers, and nitrates.
Menu